SecBot SecBot

NRIX

Nurix Therapeutics, Inc.
Nasdaq· Pharmaceutical Preparations· Inc. DE· CIK 0001549595 Biotech & Drug Discovery
$14.73 −0.75 (−4.84%)
Nov 16 4:00 PM ET · prev $15.48
Market cap
$1.7B
Small cap
Consensus
Buy
90% Buy or better · 20 analysts
Median target
$34.50
+134% · range $20.00–41.00
1 year
+15.2%
from $12.79 · Nov 17
30 days
−40.9%
from $24.93
52-week range
$12.68–27.79
−47% from high · low Nov 18
Avg volume 20D
3.86M
Nov 4 spike 19.55M
Short interest
18.94M
≈17.3% of shares · −8.1%
Days to cover
7.2
at average volume
Insider net
−$2.6M
0 buyers · 4 sellers · since Jul 30
New fund stakes
1
Q2 2026 13F · 0 exits
Filing reports
30
analyzed by SecBot
SecBot read MIXED 16 reports · 90 days
Balance 1 bearish · 2 bullish · 13 neutral oldest → newest, height = score
Avg score ·High conf. 13/16

Price

Daily candles with volume. Callouts mark insider and congressional trades, rating changes, 13F stakes, reports, catalysts, court and regulator actions, Reddit spikes and short-interest jumps. Hover one for the details (tap on phones).

Signal stack

Where each data set points today.

  • InsidersBEARISH

    4 insiders sold $2.6M.

  • InstitutionsBULLISH

    Q2 2026: 26 added (1 new), 16 trimmed or exited. Largest new: Arrowstreet Capital, Limited Partnership $11.6M.

  • AnalystsBULLISH

    18 of 20 rate it Buy or better. Every target is above the price.

  • EstimatesRISING

    Current-quarter EPS estimate −$0.369 → $1.508 over 90 days. 2 up, 0 down in 30 days.

  • Short sellersSTEADY

    Short interest −8.1% to 18.94M shares. 7.2 days to cover, ≈17.3% of shares.

  • TrendDOWNTREND

    36% below its 50-day average.

  • SocialQUIET

    No Reddit mentions this week. Last mention Nov 5.

Who's buying

13F· Q2 2026
1
new positions
0
exits
$11.6M
in new stakes
FundMoveSharesValue
Rubric Capital Management LPDOUBLED7,227,778$175.3M
PRICE T ROWE ASSOCIATES INC /MD/ADD5,436,587$131.9M
Capital World InvestorsDOUBLED1,787,916$43.4M
VANGUARD PORTFOLIO MANAGEMENT LLCADD1,482,861$36.0M
DIMENSIONAL FUND ADVISORS LPADD1,431,317$34.7M
GOLDMAN SACHS GROUP INCTRIM813,589$19.7M
RAYMOND JAMES FINANCIAL INCADD593,262$14.4M
ARROWSTREET CAPITAL, LIMITED PARTNERSHIPNEW477,141$11.6M

Quarterly 13F filings are due 45 days after each quarter ends.

The Street

20 analysts
Buy 90% rate it Buy or better
Strong Buy7Buy11Hold2Sell0Strong Sell0
12-month targets · 14 analysts

Price is below the lowest target. Median implies +134%.Targets as of Nov 16, 2026.

Recent actions
DateFirmActionRating
Nov 4, 2026Wells Fargo
MAINTAIN
MAINTAINEqual-Weight
Oct 16, 2026HC Wainwright & Co.
MAINTAIN
MAINTAINBuy
Oct 13, 2026RBC Capital
MAINTAIN
MAINTAINOutperform
Oct 13, 2026Oppenheimer
MAINTAIN
MAINTAINOutperform
Oct 13, 2026Truist Securities
MAINTAIN
MAINTAINBuy
Oct 13, 2026Baird
MAINTAIN
MAINTAINOutperform

Insider ledger

Form 4
$0
bought · 0 insiders
$2.6M
sold · 4 insiders
DateInsiderTypeValue
Nov 4, 2026
van Houte Hans
Chief Financial Officer
Nov 4, 2026
SELL$50.8K
Nov 4, 2026
van Houte Hans
Chief Financial Officer
Nov 4, 2026
SELL$23.8K
Nov 3, 2026
Ring Christine
Chief Legal Officer
Nov 3, 2026
SELL$157.9K
Nov 2, 2026
Ring Christine
Chief Legal Officer
Nov 2, 2026
SELL$245.2K
Nov 2, 2026
Ring Christine
Chief Legal Officer
Nov 2, 2026
EXERCISE$50.5K
Nov 2, 2026
Ring Christine
Chief Legal Officer
Nov 2, 2026
SELL$28.8K
Nov 2, 2026
Hansen Gwenn
Chief Scientific Officer
Nov 2, 2026
EXERCISE$2.7K
Nov 2, 2026
Hansen Gwenn
Chief Scientific Officer
Nov 2, 2026
SELL$38.9K

Earnings setup

Estimates
$1.51
EPS estimate, this quarter
+509%
estimate change, 90 days
2↑ 0↓
revisions, 30 days
Current-quarter EPS estimate
PeriodEPS est.Range30D rev.Revenue
Current Q$1.51-$0.64–$5.26+509.2%$287.9M
Next Q-$0.59-$0.59–-$0.59-34.1%$15.0M
Current FY🔒 Fresh data, subscribers only
Next FY-$1.28-$2.48–-$0.62-19.7%$123.2M

Short side

FINRA· Oct 30, 2026
18,936,583
shares short
-8.1%
vs prior settlement
7.2
days to cover
≈17.3%
of shares outstanding
Recent activity
The latest filings, insider trades, analyst actions, press and options flow, newest first.
Nov 16, 2026 SEC
🔒 Fresh report (last 24h), subscribers only
Nov 16, 2026 SEC
🔒 Fresh report (last 24h), subscribers only
Nov 16, 2026 SEC
🔒 Fresh report (last 24h), subscribers only
Nov 11, 2026 Other
Nurix Therapeutics Appoints Arati V. Rao, M.D., as Chief Medical Officer
Physician-scientist and oncology leader brings more than two decades of experience in academic medic
Nov 4, 2026 Insider
van Houte Hans sold 3,300 shares
Chief Financial Officer @ $15.38 ($50.8K)
Nov 4, 2026 Insider
van Houte Hans sold 1,469 shares
Chief Financial Officer @ $16.20 ($23.8K)
Nov 3, 2026 Insider
Ring Christine sold 6,113 shares
Chief Legal Officer @ $25.83 ($157.9K)
Oct 5, 2026 Press
Nurix Therapeutics announced a two-year extension of the research term for an undisclosed oncology program under its…
Impact 6/10
Catalysts
Scheduled dates and disclosed events: earnings, FDA and trial readouts, halts, press releases. Colored dot = impact.
5 drugs tracked · Drug pipeline →
Recent
Nov 11, 2026
Press release
Nurix Therapeutics Appoints Arati V. Rao, M.D., as Chief Medical Officer
Physician-scientist and oncology leader brings more than two decades of experience in academic medicine, global clinical development and regulatory…
Nov 3, 2026
Press release
Nurix Therapeutics Announces Sanofi’s Decision to Discontinue Development of STAT6 Degrader SAR448272
BRISBANE, Calif., Nov. 03, 2026 (GLOBE NEWSWIRE) -- Nurix Therapeutics, Inc. (Nasdaq: NRIX), a clinical-stage biopharmaceutical company focused on…
Oct 12, 2026
Earnings result
NRIX Q3 2026 Earnings: EPS $4.73 (+871.7% vs est)
Oct 7, 2026
Earnings date
NRIX Q3 2026 Earnings Scheduled, 2026-10-07
Oct 5, 2026
Contract
Nurix Therapeutics Announces Second Research Term Extension for Oncology Program Under Collaboration with Gilead Sciences
Two-year extension builds on productive relationship established in 2019

SecBot reports

30 filings · 3 press releases · 3 bullish · 3 bearish · 24 neutral
All NRIX filing & press-release reports (33)